Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

医学 索拉非尼 肝细胞癌 内科学 临床终点 危险系数 人口 肝癌 随机对照试验 肿瘤科 中止 代理终结点 胃肠病学 外科 置信区间 环境卫生
作者
Shukui Qin,Masatoshi Kudo,Tim Meyer,Yuxian Bai,Yabing Guo,Zhiqiang Meng,Taroh Satoh,Donatella Marino,Eric Assénat,Songzi Li,Yaxi Chen,Frédéric Boisserie,Ramil Abdrashitov,Richard S. Finn,Arndt Vogel,Andrew Xiuxuan Zhu
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:9 (12): 1651-1651 被引量:275
标识
DOI:10.1001/jamaoncol.2023.4003
摘要

Importance: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and additional first-line treatments are needed. The programmed cell death protein 1 inhibitor tislelizumab demonstrated efficacy and a tolerable safety profile as second-line HCC treatment. Objective: To investigate efficacy and safety of tislelizumab vs sorafenib tosylate for first-line treatment of unresectable HCC. Design, Setting, and Participants: The open-label, global, multiregional phase 3 RATIONALE-301 randomized clinical trial enrolled systemic therapy-naive adults with histologically confirmed HCC, Barcelona Clinic Liver Cancer stage B or C disease, disease progression following (or patient was not amenable to) locoregional therapy, Eastern Cooperative Oncology Group performance status of 1 or less, and Child-Pugh class A, between December 27, 2017, and October 2, 2019. Data cutoff was July 11, 2022. Intervention: Patients were randomized 1:1 to receive tislelizumab, 200 mg intravenously every 3 weeks, or sorafenib tosylate, 400 mg orally twice daily. Main Outcomes and Measures: The primary end point was overall survival (OS); secondary end points included objective response rate, progression-free survival, duration of response, and safety. Results: A total of 674 patients were included in the analysis (570 men [84.6%]; median age, 61 years [range, 23-86 years]). As of July 11, 2022, minimum study follow-up was 33 months. The primary end point of OS noninferiority of tislelizumab vs sorafenib was met in the intention-to-treat population (n = 674); median overall survival was 15.9 (95% CI, 13.2-19.7) months vs 14.1 (95% CI, 12.6-17.4) months, respectively (hazard ratio [HR], 0.85 [95.003% CI, 0.71-1.02]), and superiority of tislelizumab vs sorafenib was not met. The objective response rate was 14.3% (n = 49) for tislelizumab vs 5.4% (n = 18) for sorafenib, and median duration of response was 36.1 (95% CI, 16.8 to not evaluable) months vs 11.0 (95% CI, 6.2-14.7) months, respectively. Median progression-free survival was 2.1 (95% CI, 2.1-3.5) months vs 3.4 (95% CI, 2.2-4.1) months with tislelizumab vs sorafenib (HR, 1.11 [95% CI, 0.92-1.33]). The incidence of treatment-emergent adverse events (AEs) was 96.2% (325 of 338 patients) for tislelizumab and 100% (n = 324) for sorafenib. Grade 3 or greater treatment-related AEs were reported in 75 patients (22.2%) receiving tislelizumab and 173 (53.4%) receiving sorafenib. There was a lower incidence of treatment-related AEs leading to drug discontinuation (21 [6.2%] vs 33 [10.2%]) and drug modification (68 [20.1%] vs 187 [57.7%]) with tislelizumab vs sorafenib. Conclusions and Relevance: In RATIONALE-301, tislelizumab demonstrated OS benefit that was noninferior vs sorafenib, with a higher objective response rate and more durable responses, while median progression-free survival was longer with sorafenib. Tislelizumab demonstrated a favorable safety profile vs sorafenib. Trial Registration: ClinicalTrials.gov Identifier: NCT03412773.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英姑的应助被高凯采纳,获得10
刚刚
陈陈发布了新的文献求助10
刚刚
超越完成签到,获得积分10
1秒前
1秒前
Nora完成签到,获得积分10
1秒前
1秒前
虚幻的璟完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
苍岚完成签到,获得积分10
2秒前
Pan完成签到,获得积分10
2秒前
小嵩鼠完成签到,获得积分10
2秒前
2秒前
害怕的青荷完成签到,获得积分10
2秒前
王梦秋发布了新的文献求助10
3秒前
郑大钱完成签到,获得积分10
3秒前
花南星发布了新的文献求助10
3秒前
3秒前
难过的谷芹完成签到,获得积分10
3秒前
脑子大聪明完成签到,获得积分10
4秒前
4秒前
echo完成签到,获得积分10
4秒前
一路向阳完成签到,获得积分10
4秒前
太阳花发布了新的文献求助10
5秒前
yyyyy完成签到,获得积分10
5秒前
5秒前
6秒前
刘的花完成签到,获得积分10
6秒前
思源的应助被兵临城下zgb采纳,获得10
6秒前
中午吃什么完成签到,获得积分10
6秒前
呵呵哒完成签到,获得积分10
6秒前
共享精神的应助被CO_Pro采纳,获得10
6秒前
小鸡发布了新的文献求助10
6秒前
咸蛋黄798完成签到,获得积分10
7秒前
7秒前
7秒前
小雷完成签到,获得积分10
8秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152503
求助须知:如何正确求助?哪些是违规求助? 9549164
关于积分的说明 21691337
捐赠科研通 7740687
什么是DOI,文献DOI怎么找? 3425238
关于科研通互助平台的介绍 2550393
邀请新用户注册赠送积分活动 2468790